Aptar Pharma teams up with BD to develop novel auto-injector

Aptar Pharma has signed an exclusive development and license agreement with BD Becton, Dickinson and Company (BD).

This deal will see the joint development of a novel auto-injector using Aptar Pharma’s high performance, two-step auto-injector technology and prefillable syringes from BD.

Auto-injectors are designed to be used safely and conveniently by patients for self-injection in a non-medical environment, such as the home or office. Aptar Pharma has used feedback from market research involving patients and healthcare professionals to create a compact device capable of delivering high viscosity drugs including some of the newest biologics.

The auto-injector technology was specifically designed around the BD Neopak 1mL long glass prefillable syringe or the BD Hypak for biotech 1mL long glass prefillable syringe to ensure robustness and performance.

Under the agreement, BD and Aptar Pharma will jointly develop Aptar Pharma’s auto-injector technology platform using BD’s expertise in prefillable syringes and self-injection technologies combined with Aptar Pharma’s innovation and quality-by-design expertise.

“We are pleased to be extending our relationship with BD from pharmaceutical elastomer components supplier to now also include joint development of an auto-injector system. The key advantages of this platform hinge on the ease of use, ergonomic shape, improved feedback indicators, and the ability to handle viscous drug formulations,” said Salim Haffar, president of Aptar Pharma.